Seres Therapeutics posts 2025 profit as expenses fall

Seres Therapeutics

12/03/2026 11:14

Overview

US biotechnology firm's 2025 net income from continuing ops was $5.7 mln, reversing prior loss

2025 revenue was $789,000 as company focused on early-stage pipeline and transition services

Seres cut R&D and G&A expenses yr/yr as it prioritized inflammatory and immune disease programs

Outlook

Seres expects clinical data from SER-155 study in immune checkpoint-related enterocolitis in Q2 2026

Company expects to fund operations through Q3 2026 based on current cash position

Seres is seeking partnerships and funding to advance pipeline programs including SER-155 and SER-603

Result Drivers

LOWER OPERATING EXPENSES - Co said reduced R&D and G&A expenses were driven by lower personnel costs and decreased investment in live biotherapeutics platform

GAIN ON VOWST SALE - Installment payments from Nestle related to VOWST business sale contributed to net income

TRANSITION SERVICES PAYMENTS - Additional payments from Nestle for transition services supported results

Company press release: ID:nGNX88VDQw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Collaboration Revenue
$789,000
FY EPS
$0.64
FY Net Income
$5.70 mln
FY Operating Expenses
$94.76 mln
FY Operating Income
-$93.97 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Seres Therapeutics Inc is $21.00, about 135.2% above its March 11 closing price of $8.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)